Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT02389985Phase 2Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jul 2015
- Primary completion
- Jun 2018
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Lumos Pharma, Inc.. Started Jul 2015; status: terminated.
02
Drugs
CRLX101
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02389985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389985.